Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Petrylak Discusses the Isotope Radium-223

February 28th 2012

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Isotope Radium-223

IPCC Conference to Focus on Issues Facing Clinicians

February 22nd 2012

In March, a one-day conference will provide specialists with practical information they need to provide their patients with the best in diagnostic and therapeutic care.

Dr. Gomella Discusses the NeoACT Sipuleucel-T Study

February 15th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses the NeoACT Sipuleucel-T Study

Radiation Added to Hormone Therapy Bests Hormone Therapy Alone for High-Risk Prostate Cancer

February 9th 2012

Radiation therapy added to androgen deprivation therapy prolongs overall survival in men with locally advanced or otherwise high-risk prostate cancer.

FDA Updates: Pertuzumab Moves Forward, Denosumab Receives Setback

February 8th 2012

While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.

The Prostate Cancer Microenvironment: Implications for Therapy

February 6th 2012

In order to design new treatments for prostate cancer and prolong the lives of patients with the disease, researchers are going to have to delve into the tumor microenvironment.

Lenalidomide Plus Docetaxel: Phase III Results Fall Short

February 3rd 2012

The combination of lenalidomide and docetaxel for treatment of CRPC failed to produce results in the large phase III MAINSAIL trial.

Prostate Cancer Armamentarium Expanding

January 20th 2012

Men with prostate cancer now have an array of treatments, which was not the case a decade ago.

Benefit of ADT Added to Radiation Confined to Intermediate- Risk Prostate Cancer Patients With Poor Prognosis

January 19th 2012

Not all intermediate-risk prostate cancer patients benefit from the addition of androgen deprivation therapy to radiation therapy.

Tasquinimod Shows Potential for Metastatic Castration-Resistant Prostate Cancer

January 17th 2012

The investigational compound tasquinimod significantly postpones disease progression and increases PFS in men with minimally symptomatic, metastatic CRPC.

DNA Analysis Finds First Gene Implicated in Prostate Cancer

January 12th 2012

A statistical analysis led to the discovery of the first high-risk genetic mutation associated with hereditary prostate cancer.

Dr. Logothetis Discusses Prostate Cancer Therapy

January 11th 2012

Dr. Christopher Logothetis, from the MD Anderson Cancer Center, Discusses Prostate Cancer Therapy

Dr. Gomella Discusses Androgen-Deprivation Therapy

January 9th 2012

Dr. Leonard Gomella, from Kimmel Cancer Center, Discusses Androgen-Deprivation Therapy

Hypofractionated Radiation Trial Results Comparable to Standard in Intermediate - and High-Risk Patients

January 9th 2012

Delivering higher doses of external beam radiation in a shorter period of time was as effective as conventional radiation in preventing treatment failure in men with intermediate- to high-risk prostate cancer.

Radium-223 Properties Conducive to mCRPC Care

December 30th 2011

Radium-223, an alpha-emitting radiopharmaceutical, has been shown to improve overall survival (OS) in men with metastatic castrationresistant prostate cancer (mCRPC) in an interim analysis of the ALSYMPCA trial.

Statins linked to lower risk of prostate cancer mortality in middle-aged men

December 30th 2011

Middle-aged men taking a class of drugs called statins to reduce cholesterol levels were shown to have reduced the risk of mortality due to prostate cancer by approximately 50%, according to a new study...

Dr. Sartor on Patients in the ALSYMPCA Radium-223 Trial

December 20th 2011

Dr. Oliver Sartor, from Tulane Cancer Center, Describes Patients in the ALSYMPCA Radium-223 Trial

Men Undergoing Prostate Biopsy Have Higher Hospitalization Rates

December 20th 2011

The rate of hospitalization in older men within 30 days of a prostate biopsy is more than double that occurring in a control population not undergoing a biopsy.

Ibandronate and Radiotherapy Provide Equivalent Pain Relief in Metastatic Prostate Cancer That Has Metastasized to the Bone

December 16th 2011

A single dose of radiotherapy and a single injection of ibandronate provided similar pain relief from bone metastases in men with metastatic prostate cancer.

Castration-Resistant Prostate Cancer: A Conversation With Cora N. Sternberg, MD

December 16th 2011

Physicians and patients with castration-resistant prostate cancer (CRPC) have an increasing number of treatment options that improve outcomes.